Laurus Labs Limited has informed the Exchange about Investor Presentation
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Laurus Labs reported FY25 revenue of ₹5,554 Cr, up 10% YoY, with EBITDA surging 40% to ₹1,115 Cr and EBITDA margin expanding 430 bps to 20.1%. Net profit more than doubled to ₹358 Cr (+122% YoY), while ROCE improved to 9.7% from 6.4%. The CDMO segment was the standout, growing 42% to ₹1,534 Cr (now 28% of revenue), driven by small molecules deliveries, while Generics grew modestly 2% to ₹4,020 Cr. 4Q FY25 was particularly strong with ₹1,720 Cr revenue (+19%) and a 27.7% EBITDA margin, aided by a one-time ₹59 Cr land sale gain. Net debt/EBITDA improved to 2.3x from 2.9x, and the company declared an interim dividend of ₹0.80/share.
Strong CDMO growth and margin expansion beat management's earlier guidance of 'around 20% EBITDA margin,' likely to be viewed positively by the market. The improving revenue mix toward higher-margin CDMO work and expected normalization of asset turnovers over the next two years support a constructive outlook, though working capital and net debt remain areas to watch.